Groupama Asset Managment Cytokinetics Inc Transaction History
Groupama Asset Managment
- $5.01 Trillion
- Q1 2025
A detailed history of Groupama Asset Managment transactions in Cytokinetics Inc stock. As of the latest transaction made, Groupama Asset Managment holds 350,000 shares of CYTK stock, worth $11.8 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
350,000
Previous 350,000
-0.0%
Holding current value
$11.8 Million
Previous $421 Million
1.16%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding CYTK
# of Institutions
408Shares Held
127MCall Options Held
3.66MPut Options Held
900K-
Black Rock Inc. New York, NY14.7MShares$496 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$400 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.96MShares$336 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA7.99MShares$270 Million0.06% of portfolio
-
State Street Corp Boston, MA6.09MShares$206 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $3.18B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...